High-density reference

Overview Map

The major physiology, presentations, diagnostic patterns, treatment priorities, and anesthesia implications from this source document.

01

Main Focus

  • Differentiate endocrine islet function from exocrine pancreatic digestion.
  • Understand how insulin, glucagon, cortisol, epinephrine, and growth hormone switch the body between storage and mobilization.
  • Relate insulin receptor tyrosine-kinase signaling to GLUT4 translocation in skeletal muscle and fat.
  • Use insulin’s short half-life to predict rapid glucose change during interrupted IV infusions.
  • Recognize insulin’s intracellular potassium shift as both a treatment for hyperkalemia and a risk for hypokalemia.
  • Assess diabetic autonomic neuropathy, gastroparesis, nephropathy, thermoregulatory impairment, and stiff-joint airway risk.
  • Plan around oral agents, non-insulin injectables, insulin categories, pumps, and procedure duration.
  • Differentiate hypoglycemia, DKA, and HHS under anesthesia, where symptoms may be masked.

Presentation

  • Hypoglycemia: tachycardia, diaphoresis, tremor, anxiety, confusion, dizziness, headache, seizure, or loss of consciousness.
  • Long-standing diabetes: CAD, autonomic dysfunction, gastroparesis, nephropathy, neuropathy, reduced hypoxic response, and impaired thermoregulation.
  • Stiff-joint syndrome: positive prayer sign with reduced cervical spine and TMJ mobility despite a reassuring Mallampati score.
  • DKA: rapid onset, dehydration, fruity breath, Kussmaul respirations, abdominal pain, nausea/vomiting, ketonemia, and acidemia.
  • HHS: days-to-weeks onset, extreme hyperglycemia, profound dehydration, hyperosmolarity, confusion, lethargy, or coma with minimal ketosis.

Epidemiology

  • Type 1 diabetes accounts for roughly 5–10% of diabetes cases; type 2 for about 90–95%.
  • The endocrine islets make up only about 2% of pancreatic mass.
  • Beta cells account for roughly 60% of islet cells; alpha cells about 25%; delta cells about 10%.
  • About half of long-standing type 1 diabetic patients may have restricted joint mobility in the source guide.
  • HHS mortality is described as substantially higher than DKA mortality, largely because patients are older and more comorbid.

Etiology

  • Type 1 diabetes: autoimmune beta-cell destruction causing absolute insulin deficiency.
  • Type 2 diabetes: insulin resistance, impaired secretion, and increased hepatic glucose output.
  • Pancreatogenic diabetes: chronic pancreatitis, cystic fibrosis, or resection reduce functional islet mass.
  • DKA triggers: missed insulin, infection, trauma, acute illness, surgery, or SGLT2-associated euglycemic DKA.
  • HHS triggers: infection, sepsis, pneumonia, stroke, myocardial infarction, poor intake, or dehydration.
  • Hypoglycemia risks: insulin, sulfonylureas, meglitinides, liver disease, renal failure, gastric bypass physiology, or insulinoma.

Diagnostics

  • Fasting diabetes threshold in the guide: glucose at or above 126 mg/dL.
  • Long-term control: review HbA1c and recent glucose trends, but do not rely on HbA1c alone for day-of-surgery decisions.
  • Hypoglycemia: glucose below 70 mg/dL; symptoms often appear between 50 and 70 mg/dL.
  • DKA: hyperglycemia, ketonemia, pH below 7.3, and elevated anion gap.
  • HHS: glucose often above 600 mg/dL, osmolarity above about 350 mOsm/L, severe dehydration, and minimal ketoacidosis.
  • Unstable patients: arterial blood gas or central-lab glucose is more reliable than poorly perfused capillary sampling.

Treatment

  • Hypoglycemia: IV dextrose when access is available, recheck in 15 minutes, and use glucagon when IV access is absent.
  • DKA: isotonic fluids, potassium/electrolyte planning, insulin, and treatment of the precipitating cause.
  • HHS: careful but substantial rehydration, insulin, electrolyte replacement, hemodynamic monitoring, and trigger treatment.
  • Insulin pumps: may continue at basal rate for short uncomplicated procedures with frequent checks; longer procedures may require IV insulin and glucose.
  • Avoid sole reliance on sliding-scale bolus insulin for major or prolonged cases.
  • Use insulin plus dextrose to shift potassium intracellularly in hyperkalemia, while remembering this does not remove potassium from the body.

Pearls

  • The brain cannot rapidly switch fuels during acute hypoglycemia, making it a true anesthesia emergency.
  • Under general anesthesia, neuroglycopenic symptoms are hidden; unexplained tachycardia or diaphoresis should prompt a glucose check.
  • Insulin’s plasma half-life is about 6 minutes, so an interrupted IV infusion can change glucose quickly.
  • Glucagon requires hepatic glycogen stores and may be less effective after prolonged fasting, malnutrition, or chronic alcohol use.
  • A positive prayer sign can predict difficult airway anatomy despite a normal Mallampati score.
  • General anesthesia produces a stronger hyperglycemic stress response than regional anesthesia.
  • NPH insulin contains protamine and may increase concern for a protamine reaction during heparin reversal.
  • Perioperative medication timing should follow current local policy, especially for SGLT2 and GLP-1 drugs.